Evotec Stock Price, News & Analysis (ETR:EVT)

€14.20 0.46 (3.35 %)
(As of 01/22/2018 02:21 AM ET)
Previous Close€13.74
Today's Range€13.65 - €14.20
52-Week Range€6.65 - €22.50
Volume1.43 million shs
Average Volume1.69 million shs
Market Capitalization$2.09 billion
P/E Ratio67.62
Dividend YieldN/A
BetaN/A

About Evotec (ETR:EVT)

Evotec logoEvotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of immunology and inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, Respiratory, and Immunology and Inflammation; EVT770 for diabetes type 2/1; and EVT801, EVT701, and EVT601 for oncology. The company has alliances and partnerships with AstraZeneca AB; Bayer Pharma AG; Boehringer Ingelheim Pharma GmbH & Co. KG; CHDI Foundation, Inc.; MedImmune; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Innovation; Novartis AG; Sanofi; ex scientia Ltd; Bayer AG; Pfizer; C4X Discovery Holdings plc; Asahi Kasei Pharma Corporation; STORM Therapeutics; and ABIVAX, as well as a research collaboration with Inserm Transfert SA. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

Receive EVT News and Ratings via Email

Sign-up to receive the latest news and ratings for EVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolETR:EVT
CUSIPN/A
Phone+49-40-560810

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio67.6190476190476
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS€0.21
Net IncomeN/A
Net Margins4.35%
Return on Equity3.74%
Return on Assets2.21%

Miscellaneous

EmployeesN/A
Outstanding Shares147,270,000

Evotec (ETR:EVT) Frequently Asked Questions

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

Where is Evotec's stock going? Where will Evotec's stock price be in 2018?

4 Wall Street analysts have issued twelve-month price objectives for Evotec's stock. Their forecasts range from €14.00 to €20.00. On average, they expect Evotec's stock price to reach €16.75 in the next twelve months. View Analyst Ratings for Evotec.

Who are some of Evotec's key competitors?

Who are Evotec's key executives?

Evotec's management team includes the folowing people:

  • Wolfgang Plischke, Chairman of the Supervisory Board (Age 65)
  • Werner Lanthaler, Chief Executive Officer, Member of the Management Board (Age 49)
  • Bernd Hirsch, Vice Chairman of the Supervisory Board (Age 47)
  • Enno Spillner, Chief Financial Officer, Member of the Management Board (Age 47)
  • Mario Polywka, Chief Operating Officer, Member of the Management Board (Age 54)
  • Cord Dohrmann, Chief Scientific Officer, Member of the Management Board (Age 53)
  • Claus T. Braestrup M.D., Member of the Supervisory Board (Age 72)
  • Paul Linus Herrling Ph.D., Member of the Supervisory Board (Age 64)
  • Iris Loew-Friedrich, Member of the Supervisory Board (Age 57)
  • Michael Shalmi, Member of the Supervisory Board (Age 52)

What is Evotec's stock price today?

One share of Evotec stock can currently be purchased for approximately €14.20.

How big of a company is Evotec?

Evotec has a market capitalization of $2.09 billion.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.


MarketBeat Community Rating for Evotec (EVT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evotec (ETR:EVT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €16.75€16.75€15.33€13.00

Evotec (ETR:EVT) Consensus Price Target History

Price Target History for Evotec (ETR:EVT)

Evotec (ETR:EVT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/7/2017Berenberg BankSet Price TargetNeutral€16.00View Rating Details
12/5/2017Deutsche BankSet Price TargetBuy€17.00View Rating Details
11/29/2017Oddo BhfSet Price TargetBuy€20.00View Rating Details
8/11/2017Oddo SecuritiesSet Price TargetNeutral€14.00View Rating Details
(Data available from 1/22/2016 forward)

Earnings

Earnings History for Evotec (ETR:EVT)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Evotec (ETR:EVT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Evotec (ETR:EVT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evotec (ETR EVT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Evotec (ETR EVT) News Headlines

Source:
DateHeadline
Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi - Business Wire (press release)Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi - Business Wire (press release)
www.businesswire.com - January 8 at 11:17 AM
Evotecs Academic Bridge LAB282 with Oxford University Celebrating One Year of ImpactEvotec's Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact
finance.yahoo.com - December 11 at 9:42 AM
Deutsche Bank Reiterates €17.00 Price Target for Evotec (EVT)Deutsche Bank Reiterates €17.00 Price Target for Evotec (EVT)
www.americanbankingnews.com - December 10 at 8:42 PM
Evotec (EVT) PT Set at €16.00 by Berenberg BankEvotec (EVT) PT Set at €16.00 by Berenberg Bank
www.americanbankingnews.com - December 7 at 9:56 PM
Evotec (EVT) Given a €20.00 Price Target at Oddo BhfEvotec (EVT) Given a €20.00 Price Target at Oddo Bhf
www.americanbankingnews.com - November 29 at 7:30 AM
Evotec AG (EVT) Given a €20.00 Price Target at Oddo BhfEvotec AG (EVT) Given a €20.00 Price Target at Oddo Bhf
www.americanbankingnews.com - November 9 at 6:24 AM
Evotec AG Announces First Nine-Month 2017 Results and Corporate Update - Business Wire (press release)Evotec AG Announces First Nine-Month 2017 Results and Corporate Update - Business Wire (press release)
www.businesswire.com - November 9 at 2:51 AM
Evotec AG Announces First Nine-Month 2017 Results and Corporate UpdateEvotec AG Announces First Nine-Month 2017 Results and Corporate Update
finance.yahoo.com - November 8 at 6:41 AM
Evotec Joins Forces with Academic Leaders to Accelerate Drug Discovery in Kidney Diseases and Build NEPLEXEvotec Joins Forces with Academic Leaders to Accelerate Drug Discovery in Kidney Diseases and Build 'NEPLEX'
finance.yahoo.com - November 6 at 4:09 AM
Evotec AG to Report First Nine-Month 2017 Results on 08 November 2017 - Business Wire (press release)Evotec AG to Report First Nine-Month 2017 Results on 08 November 2017 - Business Wire (press release)
www.businesswire.com - November 3 at 11:34 PM
Evotec AG to Report First Nine-Month 2017 Results on 08 November 2017Evotec AG to Report First Nine-Month 2017 Results on 08 November 2017
finance.yahoo.com - November 2 at 7:41 PM
Evotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology Agents - Business Wire (press release)Evotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology Agents - Business Wire (press release)
www.businesswire.com - October 26 at 11:02 PM
Evotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology AgentsEvotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology Agents
finance.yahoo.com - October 26 at 12:47 PM
Evotec Achieves First Milestone in Neurodegeneration Alliance with CelgeneEvotec Achieves First Milestone in Neurodegeneration Alliance with Celgene
finance.yahoo.com - October 10 at 4:49 AM
Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery - Business Wire (press release)Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery - Business Wire (press release)
www.businesswire.com - September 28 at 6:15 PM
Berenberg Bank Reiterates "€16.00" Price Target for Evotec AG (EVT)Berenberg Bank Reiterates "€16.00" Price Target for Evotec AG (EVT)
www.americanbankingnews.com - September 19 at 6:30 AM
MARS INNOVATION AND EVOTEC AG ESTABLISH ACADEMIC BRIDGE “LAB150” IN TORONTO - GlobeNewswire (press release)MARS INNOVATION AND EVOTEC AG ESTABLISH ACADEMIC BRIDGE “LAB150” IN TORONTO - GlobeNewswire (press release)
globenewswire.com - September 14 at 7:09 PM
Evotec and MaRS Innovation Establish Academic Bridge LAB150 in TorontoEvotec and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
finance.yahoo.com - September 14 at 5:53 AM
European Investment Bank Supports Evotecs Innovate Strategy with EUR 75 M LoanEuropean Investment Bank Supports Evotec's Innovate Strategy with EUR 75 M Loan
finance.yahoo.com - September 8 at 6:55 PM
Evotec and ABIVAX Enter into Strategic Collaboration to Develop Novel Antiviral AgentsEvotec and ABIVAX Enter into Strategic Collaboration to Develop Novel Antiviral Agents
finance.yahoo.com - September 7 at 6:13 AM
Evotec to Attend Upcoming Investor ConferencesEvotec to Attend Upcoming Investor Conferences
finance.yahoo.com - September 6 at 6:25 PM
Evotec AG (EVT) Given a €16.00 Price Target by Deutsche Bank AG AnalystsEvotec AG (EVT) Given a €16.00 Price Target by Deutsche Bank AG Analysts
www.americanbankingnews.com - August 30 at 3:06 PM
Evotec AG (EVT) Given a €16.00 Price Target by Berenberg Bank AnalystsEvotec AG (EVT) Given a €16.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - August 20 at 6:22 PM
Evotec Completes Acquisition of AptuitEvotec Completes Acquisition of Aptuit
finance.yahoo.com - August 16 at 5:16 AM
Evotec AG (ETR:EVT) Given a €14.00 Price Target by Oddo Securities AnalystsEvotec AG (ETR:EVT) Given a €14.00 Price Target by Oddo Securities Analysts
www.americanbankingnews.com - August 13 at 5:50 PM
Evotecs (EVOTF) CEO Werner Lanthaler on Q2 2017 Results - Earnings Call TranscriptEvotec's (EVOTF) CEO Werner Lanthaler on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 12:49 AM
Evotec Announces First Half Year 2017 Results and Corporate UpdateEvotec Announces First Half Year 2017 Results and Corporate Update
finance.yahoo.com - August 10 at 4:40 AM
Evotec AG to Report First Half-Year 2017 Results on 10 August 2017 - Business Wire (press release)Evotec AG to Report First Half-Year 2017 Results on 10 August 2017 - Business Wire (press release)
www.businesswire.com - August 4 at 6:42 PM
Evotec and Fraunhofer IME-SP Sign Strategic Collaboration on IPSC TechnologyEvotec and Fraunhofer IME-SP Sign Strategic Collaboration on IPSC Technology
finance.yahoo.com - August 3 at 5:28 AM
Evotec AG to Report First Half-Year 2017 Results on 10 August 2017Evotec AG to Report First Half-Year 2017 Results on 10 August 2017
finance.yahoo.com - August 3 at 5:27 AM
Evotec AG (ETR:EVT) Given a €13.00 Price Target at Berenberg BankEvotec AG (ETR:EVT) Given a €13.00 Price Target at Berenberg Bank
www.americanbankingnews.com - July 31 at 9:08 AM
Evotec AG to Acquire AptuitEvotec AG to Acquire Aptuit
finance.yahoo.com - July 30 at 5:23 PM
Evotec to Acquire Aptuit, Expanding Leadership in External InnovationEvotec to Acquire Aptuit, Expanding Leadership in External Innovation
finance.yahoo.com - July 30 at 5:23 PM
Evotec Expands Collaboration with Storm Therapeutics on Its RNA Epigenetics PlatformEvotec Expands Collaboration with Storm Therapeutics on Its RNA Epigenetics Platform
finance.yahoo.com - July 27 at 5:09 AM
Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend AllianceEvotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance
finance.yahoo.com - July 24 at 9:52 AM
Evotec Received Funding from IFB Hamburg to Identify Antibody-Mediated T-cell Immunotherapies - Business Wire (press release)Evotec Received Funding from IFB Hamburg to Identify Antibody-Mediated T-cell Immunotherapies - Business Wire (press release)
www.businesswire.com - July 8 at 6:02 PM
Evotec Received Funding from IFB Hamburg to Identify Antibody-Mediated T-cell ImmunotherapiesEvotec Received Funding from IFB Hamburg to Identify Antibody-Mediated T-cell Immunotherapies
finance.yahoo.com - July 6 at 7:42 PM
Evotec Expands iPSC Drug Discovery Leadership Through Strategic Collaboration with Censo Biotechnologies - Business Wire (press release)Evotec Expands iPSC Drug Discovery Leadership Through Strategic Collaboration with Censo Biotechnologies - Business Wire (press release)
www.businesswire.com - June 29 at 4:48 PM
Evotec AG: LAB282 Accelerates with Second Round Funding - Business Wire (press release)Evotec AG: LAB282 Accelerates with Second Round Funding - Business Wire (press release)
www.businesswire.com - June 24 at 10:27 PM
Resolutions of the Annual General Meeting 2017 of Evotec AG ... - Business Wire (press release)Resolutions of the Annual General Meeting 2017 of Evotec AG ... - Business Wire (press release)
www.businesswire.com - June 14 at 6:14 PM
Evotec Joins NURTuRE Consortium to Mine Unique Kidney Disease Patient Biobank - Business Wire (press release)Evotec Joins NURTuRE Consortium to Mine Unique Kidney Disease Patient Biobank - Business Wire (press release)
www.businesswire.com - June 14 at 7:34 AM

SEC Filings

Evotec (ETR:EVT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Evotec (ETR EVT) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.